{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=32",
    "query": {
      "intervention": "Low Dose Drug A",
      "page": 32
    },
    "page_size": 10
  },
  "pagination": {
    "page": 32,
    "page_size": 10,
    "total_count": 1207,
    "total_pages": 121,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=33&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Low+Dose+Drug+A&page=31&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-17T03:33:57.768Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT05877430",
      "title": "Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "NSCLC",
        "HNSCC",
        "Melanoma",
        "Metastatic Cancer",
        "Advanced Solid Tumor",
        "Advanced Cancer"
      ],
      "interventions": [
        {
          "name": "CJRB-101",
          "type": "DRUG"
        },
        {
          "name": "Pembrolizumab injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "CJ Bioscience, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 160,
      "start_date": "2023-09-11",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2024-12-20",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 2,
      "location_summary": "Irvine, California • Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05877430"
    },
    {
      "nct_id": "NCT01673828",
      "title": "Allopregnanolone for the Treatment of Traumatic Brain Injury",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Traumatic Brain Injury",
        "Posttraumatic Epilepsy"
      ],
      "interventions": [
        {
          "name": "Allopregnanolone injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Michael A. Rogawski, MD, PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "16 Years to 65 Years"
      },
      "enrollment_count": 13,
      "start_date": "2013-04",
      "completion_date": "2016-07",
      "has_results": true,
      "last_update_posted_date": "2017-06-28",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 1,
      "location_summary": "Sacramento, California",
      "locations": [
        {
          "city": "Sacramento",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01673828"
    },
    {
      "nct_id": "NCT06408181",
      "title": "APPLE: Aspirin to Prevent Pregnancy Loss and Preeclampsia",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pre-Eclampsia",
        "Pregnancy Loss"
      ],
      "interventions": [
        {
          "name": "Aspirin 162 mg",
          "type": "DRUG"
        },
        {
          "name": "Aspirin 81mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "45 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 45 Years · Female only"
      },
      "enrollment_count": 1150,
      "start_date": "2024-06-12",
      "completion_date": "2029-06",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06408181"
    },
    {
      "nct_id": "NCT02851277",
      "title": "A Study to Evaluate Safety, Tolerability and Immune Response in Adults Allergic to Peanut After Receiving Intradermal or Intramuscular Administration of ASP0892 (ARA-LAMP-vax), a Single Multivalent Peanut (Ara h1, h2, h3) Lysosomal Associated Membrane Protein DNA Plasmid Vaccine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Peanut Allergy"
      ],
      "interventions": [
        {
          "name": "ASP0892 Intradermal",
          "type": "DRUG"
        },
        {
          "name": "ASP0892 Intramuscular",
          "type": "DRUG"
        },
        {
          "name": "Placebo Intradermal",
          "type": "DRUG"
        },
        {
          "name": "Placebo Intramuscular",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Astellas Pharma Global Development, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 31,
      "start_date": "2016-12-13",
      "completion_date": "2018-12-06",
      "has_results": false,
      "last_update_posted_date": "2024-10-23",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 8,
      "location_summary": "Little Rock, Arkansas • Mountain View, California • Baltimore, Maryland + 5 more",
      "locations": [
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Mountain View",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02851277"
    },
    {
      "nct_id": "NCT04655157",
      "title": "Safety and Efficacy in Participants With Metastatic BRAF-mutant Melanoma Treated With Encorafenib With and Without Binimetinib in Combination With Nivolumab and Low-dose Ipilimuma",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Melanoma"
      ],
      "interventions": [
        {
          "name": "encorafenib",
          "type": "DRUG"
        },
        {
          "name": "nivolumab",
          "type": "DRUG"
        },
        {
          "name": "ipilimumab",
          "type": "DRUG"
        },
        {
          "name": "binimetinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jason J. Luke, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2021-05-28",
      "completion_date": "2022-09-20",
      "has_results": true,
      "last_update_posted_date": "2024-05-23",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04655157"
    },
    {
      "nct_id": "NCT01459107",
      "title": "Human Upper Extremity Allotransplantation",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Amputation, Traumatic",
        "Wounds and Injuries",
        "Hand Injuries"
      ],
      "interventions": [
        {
          "name": "Deceased donor hand transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Bone marrow cell-based therapy & single-drug immunosuppression.",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "69 Years",
        "sex": "ALL",
        "summary": "18 Years to 69 Years"
      },
      "enrollment_count": 30,
      "start_date": "2011-07-21",
      "completion_date": "2036-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01459107"
    },
    {
      "nct_id": "NCT06171269",
      "title": "Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "Radiation",
          "type": "RADIATION"
        },
        {
          "name": "MRI",
          "type": "RADIATION"
        },
        {
          "name": "Androgen Deprivation Therapy",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "OTHER"
      ],
      "sponsor": "University of Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "MALE",
        "summary": "18 Years and older · Male only"
      },
      "enrollment_count": 60,
      "start_date": "2024-01-05",
      "completion_date": "2028-10-20",
      "has_results": false,
      "last_update_posted_date": "2026-03-04",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06171269"
    },
    {
      "nct_id": "NCT00506883",
      "title": "MPC-004 for the Treatment of an Acute Gout Flare",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "High Dose Colchicine (4.8 mg total dose)",
          "type": "DRUG"
        },
        {
          "name": "Low Dose Colchicine (1.8mg total dose)",
          "type": "DRUG"
        },
        {
          "name": "Placebo Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Takeda",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 185,
      "start_date": "2007-04",
      "completion_date": "2007-10",
      "has_results": true,
      "last_update_posted_date": "2012-11-01",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 83,
      "location_summary": "Birmingham, Alabama • Columbiana, Alabama • Huntsville, Alabama + 78 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Columbiana",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00506883"
    },
    {
      "nct_id": "NCT06365762",
      "title": "The Safety and Efficacy Study of Ethylenediaminetetraacetic Acid (EDTA) Ophthalmic Solution in Patients With Loss of Contrast Sensitivity Due to Age-Related, Low-Grade Nuclear Cataract",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Age Related Cataracts"
      ],
      "interventions": [
        {
          "name": "EDTA Ophthalmic Solution 2.6%",
          "type": "DRUG"
        },
        {
          "name": "EDTA Ophthalmic Solution 1.3%",
          "type": "DRUG"
        },
        {
          "name": "Saline Solution (Placebo)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Livionex Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "50 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "50 Years and older"
      },
      "enrollment_count": 111,
      "start_date": "2006-01-01",
      "completion_date": "2007-04-30",
      "has_results": false,
      "last_update_posted_date": "2024-04-16",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 6,
      "location_summary": "San Francisco, California • Overland Park, Kansas • Lutherville, Maryland + 3 more",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Lutherville",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Charlotte",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06365762"
    },
    {
      "nct_id": "NCT03829657",
      "title": "Phase 3 Clinical Effect Durability of TD-9855 for Treating Symptomatic nOH in Subjects With Primary Autonomic Failure",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Symptomatic Neurogenic Orthostatic Hypotension",
        "MSA",
        "Parkinson's Disease (PD)",
        "Pure Autonomic Failure (PAF)"
      ],
      "interventions": [
        {
          "name": "ampreloxetine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Theravance Biopharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "30 Years and older"
      },
      "enrollment_count": 203,
      "start_date": "2019-02-22",
      "completion_date": "2021-11-10",
      "has_results": true,
      "last_update_posted_date": "2023-01-20",
      "last_synced_at": "2026-11-17T03:33:57.768Z",
      "location_count": 20,
      "location_summary": "Sun City, Arizona • La Jolla, California • Palo Alto, California + 16 more",
      "locations": [
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Colorado Springs",
          "state": "Colorado"
        },
        {
          "city": "Boca Raton",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03829657"
    }
  ]
}